NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEVA shares have decreased by 16.1% and is now trading at $7.56. View which stocks have been mosted impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its quarterly earnings data on Wednesday, February, 12th. The company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.61 by $0.01. The business earned $4.47 billion during the quarter, compared to analysts' expectations of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 5.75% and a positive return on equity of 16.57%. The firm's revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $0.53 earnings per share. View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.

24 brokerages have issued 12-month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $11.65 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price. View analysts' price targets for Teva Pharmaceutical Industries.

Media coverage about TEVA stock has trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutTeva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Beigene (BGNE), Sarepta Therapeutics (SRPT) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Intel (INTC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Capital Research Global Investors (11.99%), Franklin Resources Inc. (1.82%), Franklin Resources Inc. (1.82%), Migdal Insurance & Financial Holdings Ltd. (1.16%), Norges Bank (0.78%) and Menora Mivtachim Holdings LTD. (0.77%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Franklin Resources Inc., Renaissance Technologies LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Commerzbank Aktiengesellschaft FI, Acadian Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, and Nuveen Asset Management LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, and Richard Daniell. View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Menora Mivtachim Holdings LTD., Migdal Insurance & Financial Holdings Ltd., Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., Banco Bilbao Vizcaya Argentaria S.A., Beck Mack & Oliver LLC, and Van ECK Associates Corp. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $7.56.

Teva Pharmaceutical Industries has a market capitalization of $8.26 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe. View additional information about Teva Pharmaceutical Industries.

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]